Kronos Bio, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. 

At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma.

Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology.

For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.

Sign up for free to view info

Email Format Employee directory